| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income, net | 2,785 | 3,258 | 3,709 | 4,779 |
| Loss before income taxes | -27,809 | -33,367 | -30,984 | -9,001 |
| Income tax provision | 83 | 15 | 37 | 43 |
| Net loss | -27,892 | -33,382 | -31,021 | -9,044 |
| Net unrealized gain on available-for-sale securities | 228 | -22 | 208 | 489 |
| Total other comprehensive income | 228 | -22 | 208 | 489 |
| Comprehensive loss | -27,664 | -33,404 | -30,813 | -8,555 |
| Earnings per share, basic | -0.47 | -0.57 | -0.53 | -0.16 |
| Earnings per share, diluted | -0.47 | -0.57 | -0.53 | -0.16 |
| Weighted average number of shares outstanding, basic | 58,803,015 | 58,666,460 | 58,349,769 | 57,851,110 |
| Weighted average number of shares outstanding, diluted | 58,803,015 | 58,666,460 | 58,349,769 | 57,851,110 |
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)